Jean-Claude Barats

Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens

Andreas du Bois, B. Weber, Justine Rochon et al. · Journal of Clinical Oncology · 2006 · 196 citations · Full text

Disease-Free Survival Advantage of Weekly Epirubicin Plus Tamoxifen Versus Tamoxifen Alone As Adjuvant Treatment of Operable, Node-Positive, Elderly Breast Cancer Patients: 6-Year Follow-Up Results of the French Adjuvant Study Group 08 Trial

P. Fargeot, Jacques Bonneterre, Henri Roché et al. · Journal of Clinical Oncology · 2004 · 106 citations · Full text

Long-Term Cardiac Follow-Up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, As Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group

Jacques Bonneterre, Henri Roché, Pierre Kerbrat et al. · Journal of Clinical Oncology · 2004 · 99 citations · Full text

Heart Failure, Breast Oncology, Cardiac Risk Factors +19

Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission

P. Dufour, Jean‐Pierre Bergerat, Jean-Claude Barats et al. · Cancer · 1994 · 40 citations · Full text